Aortic Valve Insufficiency

11

Review clinical trials related to Aortic Valve Insufficiency. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

To demonstrate non-inferiority of the Trilogy Transcatheter Heart Valve (THV) System compared with surgical aortic valve replacement (SAVR) for treatment of subjects with clinically significant native aortic regurgitation (AR)

Participants needed: 1,016
Trial details
Biological sex: AllType: InterventionalSponsor: JenaValve Technology, Inc.Updated: Jun 25, 2026Locations: 28
Eligibility criteria

Class I or II indication for AVR according to ACC/AHA or ESC/EACTS guidelines wi... [+4]

Confirmed moderate (2+) or less AR severity by core laboratory evaluation [+51]

Status: Recruiting

Von Willebrand Factor Point-of-care Testing to Improve Minimally Invasive TAVI Outcomes

Paravalvular regurgitation (PVR) is an important complication of Transcatheter Aortic Valve Implantation (TAVI) that is associated with a 2.5-fold increase risk of mortality. Transesophageal echocardiographic (TEE) is considered as the gold standard to assess the severity of PVR and guide the physician to perform corrective procedures during TAVI, but it requires general anesthesia (GA). With such approach (TEE+GA), the PARTNERII trial has demonstrated that very low rate of PVR (3,5%) can be achieved with current devices. Registries have demonstrated a strong trend for using a mini-invasive approach in which the procedure is performed under conscious sedation (CS) without TEE. However, several studies raised concerns on the safety of this mini-invasive approach concerning the PVR rate. Thus, the accurate and real-time assessment of the presence and severity of PVR is an unmet clinical need to optimize TAVI without TEE guidance. A recent study reported that a blood biomarker reflecting the Von Willebrand factor (VWF) activity, i.e. the closure time with adenosine diphosphate (CT-ADP), is a valuable non-invasive, highly reproducible, and easy to perform alternative to TEE for PVR evaluation. The hypothesis is that the measurement of CT-ADP during TAVI performed without TEE guidance can improve both the detection of significant PVR and thus the procedural and clinical outcomes (primary objective).

Participants needed: 944
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University Hospital, LilleUpdated: May 22, 2026Locations: 9
Eligibility criteria

All patients scheduled to undergo mini-invasive TAVI at any of the participating... [+3]

TAVI through non-transfemoral approach [+7]

Status: Recruiting

The JenaValve ALIGN-AR LVAD Registry

To evaluate the safety and effectiveness of the JenaValve Trilogy™ Heart Valve System for transcatheter aortic valve replacement (TAVR) in subjects with continuous flow left ventricular assist devices (cfLVAD) and clinically significant aortic regurgitation (AR) who are indicated for TAVR

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: JenaValve Technology, Inc.Updated: Apr 1, 2026Locations: 15
Eligibility criteria

Patient with NYHA functional class III/IV [+4]

Congenital uni- or bicuspid (Sievers 0) aortic valve morphology [+20]

Status: Recruiting

ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy

The overall purpose of ART trial is to establish the Safety and Efficacy of the J-VALVE Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients with Grade≥3+ Native Aortic Regurgitation.

Participants needed: 1,250
Trial details
Age: 65+Biological sex: AllType: InterventionalSponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityUpdated: Mar 10, 2026Locations: 12
Eligibility criteria

1) Age ≥65 years; [+8]

1. Confirmed moderate or less AR severity (Grade≤2+) by core laboratory evaluati... [+54]

Status: Recruiting

Transpacific TAVR Registry

This registry evaluates the long-term outcome of Transcatheter aortic valve replacement (TAVR) in real-world clinical practice.

Participants needed: 10,000
Trial details
Age: 19+Biological sex: AllType: ObservationalSponsor: Duk-Woo Park, MDUpdated: Jan 2, 2026Locations: 7
Eligibility criteria

All patients undergoing TAVR [+1]

Status: Recruiting

ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.

Participants needed: 200
Trial details
Biological sex: AllType: InterventionalSponsor: Edwards LifesciencesUpdated: Dec 22, 2025Locations: 35
Eligibility criteria

Failing aortic bioprosthetic valve demonstrating ≥ moderate stenosis and/or ≥ mo... [+4]

Anatomical characteristics that would preclude safe femoral placement of the int... [+31]

Status: Not yet recruiting

Comparison of Early Postoperative Outcomes Between Minimally Invasive Valve Surgery Via Right Thoracotomy and Conventional Valve Surgery Via Sternotomy.

This randomized controlled trial aims to compare early postoperative outcomes between Minimally Invasive Valve Surgery (MIVS) via right thoracotomy and Conventional Valve Surgery via median sternotomy in patients undergoing elective, isolated mitral or aortic valve surgery. Minimally invasive techniques are believed to reduce postoperative pain, ventilation time, chest drain output, and wound complications, but evidence from Pakistan is limited. The study will enroll patients of all ages and genders who are scheduled for isolated valvular procedures at Chaudhary Pervaiz Elahi Institute of Cardiology (CPEIC), Multan. Participants will be randomly assigned to undergo either minimally invasive thoracotomy or conventional sternotomy. Primary outcomes include ventilation time, CPB duration, cross-clamp time, pain scores, and chest drain output. Secondary outcomes include wound healing (Day 7 and 30 days), return to routine activity, echocardiographic evaluation, transfusion requirements, and 30-day mortality. Findings from this study may provide evidence to guide the adoption of minimally invasive valvular surgery techniques in low-resource and developing settings.

Participants needed: 32
Trial details
Biological sex: AllType: InterventionalSponsor: Chaudhry Pervaiz Elahi Institute of CardiologyUpdated: Nov 26, 2025
Eligibility criteria

Patients of any age and gender. [+4]

Emergency or redo cardiac surgeries [+5]

Status: Not yet recruiting

Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice

Valvular heart disease (VHD) is a growing public health concern globally, with increasing disease burden and rising interest in advanced treatment strategies such as transcatheter interventions. However, there remains a significant lack of real-world data regarding echocardiography practices, disease prevalence and progression, referral patterns, and treatment pathways. Addressing these gaps is critical for improving patient care and informing clinical decision-making. South Korea provides a unique opportunity to conduct a nationwide retrospective echocardiographic study due to its advanced healthcare infrastructure, high patient volume, and strong tradition in clinical research. The current study aims to evaluate the real-world burden and clinical journey of patients with moderate or severe valvular disease over a 10-year period, based on echocardiographic and electronic medical record (EMR) data collected from multiple tertiary centers across the country.

Participants needed: 30,000
Trial details
Age: 19+Biological sex: AllType: ObservationalSponsor: Yonsei UniversityUpdated: Jul 16, 2025Locations: 1
Eligibility criteria

Period: 2010.1.1~2020.12.31 [+3]

Poor image of echocardiography [+1]

Status: Recruiting

Avalus European Registry - an Observational Study to Evaluate Safety and Efficacy in a Real World Population

This is a prospective, observational, single-arm, multi-center registry of patients undergoing bioprosthetic aortic valve replacement with the Avalus valve. This prospective registry aims to examine the outcome and performance of surgical aortic valve replacement with the Avalus pericardial bioprosthesis.

Participants needed: 1,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Universitaire Ziekenhuizen KU LeuvenUpdated: Jul 1, 2024Locations: 19Duration: 1 Year
Eligibility criteria

Clinical indication for replacement of the native or prosthetic aortic valve wit... [+2]

Patient requires salvage surgery (according to EuroSCORE II definitions: "patien... [+1]

Status: Recruiting

European Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study

This study aims to investigate the prevalence and characteristics of multiple and mixed valvular heart disease (MMVD), which includes combinations of stenotic or regurgitant lesions on cardiac valves. The research will be conducted as a multicenter observational study, involving several centers worldwide, and will have a one-year follow-up period (with a possible extension to 5 years). The primary aim is to determine the proportion of MMVD among patients evaluated for valvular heart disease. Secondary aims include the evaluation of the epidemiologic distribution of clinical, biological, and cardiovascular imaging characteristics at baseline, management strategies, and their impact on prognosis. The study will also evaluate clinical outcomes such as mortality, hospitalization for heart failure, and changes in echocardiographic parameters. This research aims to provide valuable insights into the diagnosis, management, and prognosis of MMVD, addressing an important knowledge gap in this area.

Participants needed: 1,500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Assistance Publique - Hôpitaux de ParisUpdated: Jun 3, 2024Locations: 1
Eligibility criteria

Age ≥ 18 years [+4]

History of prior valve surgery or percutaneous valve intervention (concerning a... [+2]

Status: Recruiting

Results of the Aortic Valve Reconstruction in Children

Aortic valve disease counts up to 5% of cases of congenital heart disease being one of the most common congenital malformations of the cardiovascular system. This disease requires replacement of the damaged valve which in itself is not a trivial task to complete in children as there is still no available best practice for valve replacement. Today, the following alternative variants are performed in children: mechanical aortic prosthesis, xenografts, allografts, and pulmonary autograft (Ross procedure) and each has its potential advantages and disadvantages. Mechanical aortic prostheses require lifelong anticoagulation therapy and repeated surgeries to replace mechanical valves during child growth. Available xenografts in children also has suboptimal results not only because of absence of growth potential, but also due to development of degenerative changes in biological tissue of the graft leaflets. Allograft tissues are exposed to rapid biodegradation in the recipient body and thus requiring repeated surgeries associated with higher difficulty, high risk of hemorrhages, and injury of the coronary injuries. Ross procedure was proposed as theoretically the most evidence-based reconstruction of the aortic valve in children. Even successfully performed Ross operation transforms one-valve disorder into two-valve disease. The accumulation of knowledge on the anatomy of the aortic root and improvement of surgical techniques led to the development of new methods for reconstruction of the valve function. The technique is widely applied in adult cardiac surgery, uses glutaraldehyde-treated autopericardium for augmentation of the leaflets. Absence of foreign material provides no need for anticoagulation therapy. Potentially, reconstruction of the aortic valve with autopericardium can be widely used in children. Aim is to study safety, clinical and hemodynamic efficacy of the method of the aortic valve reconstruction with autopericardium in children with aortic valve disease. Patients aged 29 days to 12 years will be included into the study. The data according to the protocol of the study will be assessed at the stage of inclusion, during the surgery, in 30 days after the surgery, and in 1, 2, and 3 years after the surgery. Data about all the patients included into the research will be analyzed in order to study the endpoints and achieve the research aim.

Participants needed: 40
Trial details
Age: 29-12Biological sex: AllType: ObservationalSponsor: National Medical Research Center for Children's Health, Russian FederationUpdated: Mar 3, 2021Locations: 1
Eligibility criteria

Age from 29 days to 12 years [+14]